JP Morgan Chase
PRLD icon

JP Morgan Chase’s Prelude Therapeutics PRLD Stock Holding History

JP Morgan Chase’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$190 Hold
62
– – ﹤0.01% 7255
2025
Q4 		$180 Sell
62
-3,817
-98% -$6.44K ﹤0.01% 7169
2025
Q3 		$5.58K Buy
3,879
+1,930
+99% +$1.93K ﹤0.01% 6754
2025
Q2 		$1.58K Sell
1,949
-21,831
-92% -$18.9K ﹤0.01% 6569
2025
Q1 		$18.3K Sell
23,780
-37,369
-61% -$34.9K ﹤0.01% 6172
2024
Q4 		$78K Buy
61,149
+55,183
+925% +$73.2K ﹤0.01% 5847
2024
Q3 		$12.3K Buy
5,966
+106
+2% +$491 ﹤0.01% 6331
2024
Q2 		$22.3K Sell
5,860
-387
-6% -$1.57K ﹤0.01% 6106
2024
Q1 		$29.6K Sell
6,247
-3,133
-33% -$12.2K ﹤0.01% 6119
2023
Q4 		$40.1K Sell
9,380
-7,973
-46% -$24.3K ﹤0.01% 6062
2023
Q3 		$53.6K Buy
17,353
+8,014
+86% +$30.1K ﹤0.01% 5782
2023
Q2 		$42K Buy
9,339
+7,945
+570% +$47.5K ﹤0.01% 5757
2023
Q1 		$8K Buy
1,394
+97
+7% +$592 ﹤0.01% 6170
2022
Q4 		$8K Sell
1,297
-1,154
-47% -$7.39K ﹤0.01% 6084
2022
Q3 		$16K Buy
2,451
+418
+21% +$2.82K ﹤0.01% 5865
2022
Q2 		$11K Sell
2,033
-7,231
-78% -$36.8K ﹤0.01% 6015
2022
Q1 		$64K Buy
9,264
+2,040
+28% +$18.7K ﹤0.01% 5700
2021
Q4 		$91K Buy
7,224
+205
+3% +$3.33K ﹤0.01% 5725
2021
Q3 		$220K Buy
7,019
+130
+2% +$4.21K ﹤0.01% 5178
2021
Q2 		$197K Buy
6,889
+594
+9% +$21.1K ﹤0.01% 5255
2021
Q1 		$273K Sell
6,295
-18,201
-74% -$1.21M ﹤0.01% 5018
2020
Q4 		$1.75M Buy
+24,496
New +$1.22M ﹤0.01% 3570

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Chase's PRLD Position: Q1 2026 in Review

JP Morgan Chase held its Prelude Therapeutics (PRLD) position steady in Q1 2026 at 62 shares worth $190. The position accounts for ﹤0.01% of the portfolio, ranked #7255.

JP Morgan Chase first reported a position in PRLD in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.75M in Q4 2020. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • JP Morgan Chase held 62 shares of Prelude Therapeutics worth $190 as of Q1 2026.
  • JP Morgan Chase left its Prelude Therapeutics share count unchanged in Q1 2026.
  • Prelude Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7255 holding.
  • JP Morgan Chase first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • JP Morgan Chase's Prelude Therapeutics position peaked at $1.75M in Q4 2020.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.